ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Zoetis Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$79.59+0.21 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $33.24B
- P/E (TTM)
- 13.1
- Dividend yield
- 2.55%
Zoetis Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | $4.91B | $5.00B | $5.10B | $5.12B | $5.14B | $5.09B | $5.07B | $5.03B | $4.86B | $4.71B | $4.56B | $4.46B | 51.6% | -4.4% |
| International | $4.50B | $4.41B | $4.25B | $4.16B | $4.13B | $4.08B | $4.10B | $4.05B | $3.98B | $3.94B | $3.91B | $3.83B | 47.3% | +8.9% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total products and services | $9.41B | $9.41B | $9.35B | $9.28B | $9.27B | $9.17B | $9.18B | $9.07B | $8.84B | $8.65B | $8.47B | $8.29B | 98.9% | +1.5% |
| Companion animal | $6.48B | $6.56B | $6.59B | $6.55B | $6.51B | $6.37B | $6.28B | $6.16B | $5.96B | $5.80B | $5.58B | $5.43B | 68.1% | -0.5% |
| Horses | $6.30B | $6.29B | $6.28B | $6.00B | $5.99B | $5.99B | $5.99B | $5.29B | $5.29B | $5.29B | $5.29B | $4.95B | 66.2% | +5.0% |
| Livestock | $2.93B | $2.85B | $2.76B | $2.73B | $2.76B | $2.81B | $2.90B | $2.92B | $2.88B | $2.85B | $2.89B | $2.86B | 30.8% | +6.2% |
| Parasiticides | $2.39B | $2.35B | $2.34B | $2.32B | $2.28B | $2.22B | $2.15B | $2.12B | $2.05B | $2.02B | $1.95B | $1.91B | 25.1% | +4.8% |
| Vaccines | $2.05B | $2.04B | $1.96B | $1.91B | $1.88B | $1.81B | $1.83B | $1.83B | $1.81B | $1.79B | $1.77B | $1.73B | 21.5% | +9.0% |
| Dermatology | $1.65B | $1.72B | $1.75B | $1.75B | $1.73B | $1.67B | $1.66B | $1.61B | $1.56B | $1.50B | $1.43B | $1.40B | 17.3% | -4.5% |
| Cattle | $1.60B | $1.53B | $1.49B | $1.46B | $1.45B | $1.48B | $1.53B | $1.53B | $1.52B | $1.50B | $1.50B | $1.48B | 16.8% | +9.8% |
| Anti-infectives | $1.05B | $1.03B | $1.04B | $1.03B | $1.02B | $1.06B | $1.10B | $1.08B | $1.07B | $1.05B | $1.06B | $1.08B | 11.1% | +3.7% |
| Pain and sedation | $833.00M | $839.00M | $840.00M | $851.00M | $866.00M | $864.00M | $851.00M | $828.00M | $756.00M | $680.00M | $602.00M | – | 8.8% | -3.8% |
| Other pharmaceutical | $692.00M | $699.00M | $697.00M | $691.00M | $682.00M | $660.00M | $658.00M | $642.00M | $639.00M | $656.00M | $678.00M | $786.00M | 7.3% | +1.5% |
| Swine | $476.00M | $477.00M | $466.00M | $462.00M | $482.00M | $494.00M | $516.00M | $527.00M | $525.00M | $528.00M | $543.00M | $542.00M | 5.0% | -1.2% |
| Animal health diagnostics | $461.00M | $448.00M | $434.00M | $424.00M | $415.00M | $408.00M | $386.00M | $378.00M | $372.00M | $365.00M | $376.00M | $369.00M | 4.8% | +11.1% |
| Poultry | $456.00M | $445.00M | $432.00M | $433.00M | $466.00M | $494.00M | $527.00M | $537.00M | $525.00M | $524.00M | $524.00M | $512.00M | 4.8% | -2.1% |
| Fish | $308.00M | $306.00M | $286.00M | $279.00M | $271.00M | $252.00M | $242.00M | $239.00M | $226.00M | $216.00M | $220.00M | $219.00M | 3.2% | +13.7% |
| Other non-pharmaceutical | $270.00M | $268.00M | $263.00M | $268.00M | $266.00M | $263.00M | $253.00M | $249.00M | $248.00M | $247.00M | $254.00M | $259.00M | 2.8% | +1.5% |
| Contract manufacturing & human health | $105.00M | $109.00M | $116.00M | $107.00M | $105.00M | $90.00M | $80.00M | – | – | – | – | – | 1.1% | 0.0% |
| Sheep and other | $96.00M | $95.00M | $88.00M | $93.00M | $89.00M | $84.00M | $82.00M | $81.00M | $83.00M | $89.00M | $100.00M | $103.00M | 1.0% | +7.9% |
| Medicated feed additives | – | – | $27.00M | $66.00M | $152.00M | $221.00M | $293.00M | $339.00M | $334.00M | $344.00M | $354.00M | $356.00M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total geographical area | $9.41B | $9.41B | $9.35B | $9.28B | $9.27B | $9.17B | $9.18B | $9.07B | $8.84B | $8.65B | $8.47B | $8.29B | 98.9% | +1.5% |
| United States | $4.91B | $5.00B | $5.10B | $5.12B | $5.14B | $5.09B | $5.07B | $5.03B | $4.86B | $4.71B | $4.56B | $4.46B | 51.6% | -4.4% |
| Other emerging markets | $1.00B | $954.00M | $913.00M | $884.00M | $876.00M | $875.00M | $865.00M | $849.00M | $816.00M | $797.00M | $784.00M | $782.00M | 10.5% | +14.2% |
| Other developed markets | $702.00M | $690.00M | $641.00M | $623.00M | $607.00M | $570.00M | $564.00M | $551.00M | $530.00M | $517.00M | $512.00M | $488.00M | 7.4% | +15.7% |
| Brazil | $405.00M | $395.00M | $393.00M | $387.00M | $388.00M | $394.00M | $414.00M | $418.00M | $418.00M | $410.00M | $393.00M | $373.00M | 4.3% | +4.4% |
| Australia | $354.00M | $343.00M | $329.00M | $329.00M | $325.00M | $325.00M | $319.00M | $314.00M | $315.00M | $314.00M | $323.00M | $312.00M | 3.7% | +8.9% |
| United Kingdom | $321.00M | $330.00M | $325.00M | $321.00M | $319.00M | $311.00M | $314.00M | $298.00M | $296.00M | $286.00M | $277.00M | $270.00M | 3.4% | +0.6% |
| Canada | $295.00M | $294.00M | $290.00M | $286.00M | $282.00M | $286.00M | $277.00M | $274.00M | $271.00M | $266.00M | $255.00M | $249.00M | 3.1% | +4.6% |
| Germany | $255.00M | $243.00M | $236.00M | $233.00M | $228.00M | $229.00M | $225.00M | $220.00M | $213.00M | $208.00M | $202.00M | $192.00M | 2.7% | +11.8% |
| China | $220.00M | $225.00M | $227.00M | $232.00M | $248.00M | $249.00M | $270.00M | $270.00M | $278.00M | $294.00M | $320.00M | $346.00M | 2.3% | -11.3% |
| Mexico | $180.00M | $172.00M | $160.00M | $155.00M | $153.00M | $160.00M | $169.00M | $172.00M | $175.00M | $167.00M | $162.00M | $154.00M | 1.9% | +17.6% |
| France | $169.00M | $171.00M | $165.00M | $166.00M | $162.00M | $154.00M | $156.00M | $151.00M | $149.00M | $149.00M | $142.00M | $137.00M | 1.8% | +4.3% |
| Spain | $158.00M | $155.00M | $145.00M | $137.00M | $134.00M | $127.00M | $130.00M | $128.00M | $123.00M | $121.00M | $122.00M | $115.00M | 1.7% | +17.9% |
| Japan | $149.00M | $151.00M | $154.00M | $147.00M | $146.00M | $142.00M | $147.00M | $147.00M | $148.00M | $156.00M | $158.00M | $156.00M | 1.6% | +2.1% |
| Italy | $149.00M | $146.00M | $137.00M | $136.00M | $132.00M | $131.00M | $129.00M | $129.00M | $124.00M | $123.00M | $121.00M | $112.00M | 1.6% | +12.9% |
| Chile | $141.00M | $141.00M | $139.00M | $128.00M | $130.00M | $127.00M | $123.00M | $124.00M | $124.00M | $132.00M | $140.00M | $144.00M | 1.5% | +8.5% |
From the segment and revenue-disaggregation notes of Zoetis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.